Interventional Glaucoma

Andrew Iwach, MD, co-founder of the Glaucoma 360 meeting shares that value this meeting has for residents and fellows as they embark on their careers and the future additions to the meeting that will include retina discussions.

Inder Paul Singh, MD, speaks to the potential of artificial intelligence (AI) in the management of the glaucoma disease state as well as the current challenges of drug delivery in treating patients with glaucoma.

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, with a good safety profile.

Andrew Iwach, MD, shares how Glaucoma 360 got its start and how today's meeting focuses on innovation that can benefit patients with glaucoma as the condition is monitored and treated.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

Real-world scenarios showcase a shift in treatment paradigms

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

Recipients will be awarded $100,000 to support a collaborative project related to glaucoma

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

Himani Goyal, MD, discusses a complex glaucoma case involving persistent intraocular pressure elevation despite multiple treatment procedures, focusing on advanced management strategies and decision-making for challenging cases.

Himani Goyal, MD, explores a case of glaucoma treated with an intracameral implant, evaluating its efficacy in managing intraocular pressure and its role in optimizing long-term glaucoma care.

Himani Goyal, MD, discusses a case of cataracts and minimally invasive glaucoma surgery (MIGS) combination, highlighting the benefits of this approach in managing both cataracts and glaucoma in a single procedure for improved patient outcomes.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

Himani Goyal, MD, assesses the benefits of proactive glaucoma management through interventional procedures beyond traditional treatments, focusing on treatment customization based on factors such as visual potential, glaucoma staging, IOP targets, comorbid conditions, and patient preferences.

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, and a dedicated webpage.

Lana Rifkin, MD, a uveitis specialist at Ophthalmic Consultants of Boston, shared insights into her work and her role as committee chair of the uveitis section for the upcoming EnVision Summit, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

Our top 10 print stories highlight the core content concepts we explored this year

According to Iridex Corp., the study confirms MicroPulse TLT's sustained safety and efficacy in managing glaucoma, reducing intraocular pressure and medication reliance with minimal complications over 5 years.

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a promising new approach for open-angle glaucoma management.

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating glaucoma, particularly in conjunction with cataract surgery.

According to the partners, glaucoma research to be led by internationally renowned glaucoma surgeon Ike Ahmed, MD, FRCSC, distinguished research scientist Fiona McDonnell, PhD, and Ian Pitha, MD, PhD, associate director of the Alan S. Crandall Center for Glaucoma Innovation

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ophthalmic models suggest potential for treating dry AMD, glaucoma, and neurodegenerative eye diseases.